331 related articles for article (PubMed ID: 26796600)
1. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
2. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
4. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
5. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
7. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
[TBL] [Abstract][Full Text] [Related]
8. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
9. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
11. Cyto-morphologic evaluation of bone marrow in infants with disseminated neuroblastoma.
Sorrentino S; Rosanda C; Parodi S; Rita Gigliotti A; Pasino M; Defferrari R; Tonini GP; De Bernardi B
J Pediatr Hematol Oncol; 2012 Mar; 34(2):154-8. PubMed ID: 22367387
[TBL] [Abstract][Full Text] [Related]
12. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
13. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
14. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
[TBL] [Abstract][Full Text] [Related]
15. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
16. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
17. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
[TBL] [Abstract][Full Text] [Related]
18. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
20. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]